文献类型：期刊文献

英文题名：A Non-Invasive Transtympanic Bioadhesive Hydrogel for Otitis Media Effusion Therapy

作者：Wan, Qian[1]; Liu, Hanwei[1]; Sun, Shizhe[2]; Wang, Ruotong[1]; Lai, Jingwei[1]; Shi, Wendi[3]; Xu, Yuanyuan[1]; Jiang, Yumeng[1,5]; Hu, Xianchuang[2]; Li, Ziyuan[2]; Zhu, Minhui[4]; Zhang, Junji[2]; Shi, Haibo[1]; Tian, He[2]

机构：[1] Department of Otorhinolaryngology Head & Neck Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; [2] Institute of Fine Chemicals, School of Chemistry and Molecular Engineering, East China University of Science and Technology, Shanghai, China; [3] Hangzhou Ren-Ai Hearing Rehabilitation Research Center, Hui'er Artificial Intelligence Hearing Research Center, Hangzhou, China; [4] Department of Otorhinolaryngology Head & Neck Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China; [5] Otolaryngological Institute

年份：2026

外文期刊名：SSRN

收录：EI(收录号：20260154469)

语种：英文

外文关键词：Controlled drug delivery - Diseases - Drug products - Gelation - Hydrogels - Rats - Targeted drug delivery

摘要：Otitis media with effusion (OME) is a highly prevalent condition characterized by persistent inflammatory effusion in the middle ear cavity. Current treatment remains clinically challenging due to the anatomical inaccessibility of the middle ear, which limits drug efficacy and often necessitates invasive surgical interventions. To address this, we engineered a transtympanic hydrogel platform (Gel-HADA) that undergoes rapid, enzyme-mediated gelation on the tympanic membrane (TM), forming a "second membrane" through transglutaminase (TGase) crosslinking within 15 minutes. This hydrogel adheres firmly to the TM, degrades controllably over 7 days, and allows sustained drug release modulated by crosslinking density. As a result, dexamethasone phosphate disodium-loaded Gel-HADA (Gel-HADA-Dex) demonstrated effective permeability across ex vivo rat TMs. In a rat OME model, a single Gel-HADA-Dex administration potently suppressed mucosal inflammation, restored middle ear function, and reversed TM thickening, outperforming conventional dexamethasone solution. Mechanistically, Gel-HADA-Dex normalized the aberrant immune‐transcriptional network and suppressed key pro‐inflammatory cytokines while enhancing anti‐inflammatory mediators. The hydrogel demonstrated excellent biocompatibility, hemocompatibility, and auditory safety with no ototoxic effects. Together, the study established Gel-HADA as the first non-invasive transtympanic corticosteroid delivery system and a robust, clinically translatable therapeutic strategy for localized treatment of OME, offering a paradigm shift from current invasive or systemic approaches toward targeted, sustained pharmacotherapy in otology. ? 2026, The Authors. All rights reserved.